Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

Viruses can deliver light-sensitive proteins to specific cells in the retinas of blind mice, allowing rudimentary vision, according to new research. Although previous studies have shown that the light-sensitive proteins can be beneficial, the delivery methods were not practical for humans. The viral-delivery method is similar to ones already used in human gene therapy.

The new light-sensitive proteins were active for the length of the study, about 10 months, suggesting the treatment would work long-term. In addition, the therapy appeared safe; the proteins, which were derived from algae, remained within the eye, and they did not trigger inflammation.

“In my opinion, the biggest step forward in this paper is the use of viral delivery techniques, the same delivery techniques that would have to be used should the technique move on into human treatment,” says Thomas Münch, a researcher at the University of Tübingen, who was not involved in the study but has done similar research. Recent gene-therapy studies, which used similar viruses to deliver different proteins, have shown preliminary success in treating a rare genetic form of blindness in patients.But the current approach could be applied to a much broader group of people because it could restore light-sensitivity to the retina regardless of the cause of degeneration.

To restore vision, Alan Horsager, a researcher at the University of Southern California, and collaborators capitalized on optogenetics, a type of genetic engineering that makes neurons sensitive to light. They used a specially designed virus to deliver numerous copies of the gene that makes a protein called channelrhodopsin to the eye. The protein forms a channel that sits on a cell’s membrane and opens when exposed to light. Positively charged ions then rush into the cell, triggering an electrical message that is transferred to other cells in the retina.

The gene was modified so that it became active only in specific retinal cells called bipolar cells. In a healthy eye, these cells are activated when adjacent photoreceptor cells detect light. The researchers hope that making the bipolar cells directly responsive to light in an eye stricken by retinal degenerative diseases, such as retinitis pigmentosa or macular degeneration, could enable the altered cells to replace photoreceptors that have died off. Horsager cofounded a startup called Eos Neuroscience, along with MIT neuroscientist Ed Boyden, to commercialize the approach.

1 comment. Share your thoughts »

Credit: Mehdi Doroudchi
Video by Brittany Sauser, Alan Horsager's Lab at USC, and the McGovern Institute for Brain Research at MIT, edited by JR Rost

Tagged: Biomedicine, blindness, optogenetics, retinitis pigmentosa, channelrhodospin

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me